Cell and gene therapy landscape assessment

Global development landscape assessment of multiple ATMPs to support commercial decision making

This project utilised the Lightning Insights platform

Scope:

Global

Therapy Area:

Orphan disease

Client:

Global pharmaceutical company

The Challenge

The client required an evaluation of pipeline products for an orphan disease to inform planning and investment decisions

Project objectives

To guide the client team through the identification and evaluation of ATMPs in development for rare ophthalmology indications, including landscape analysis, recommendations of ‘ones to watch’, commercial forecasting and strategic evaluation for priority assets

Approach

Secondary research of the clinical landscape and pipeline analysis, followed by a KOL and payer primary research programme to validate the clinical opportunity and pricing & market access potential for priority assets. A commercial forecast was developed, and priority assets were scored using primary research outputs

VALUE DELIVERED

An evidence-based evaluation of the global development landscape was delivered including a SWOT analysis and a commercial forecast model projecting revenue potential and market share for each priority asset

Related case studies

Process development

Re-defining the opportunity assessment process for a global medical technology company

Full due-diligence process

Supporting a global medical device manufacturer with a full due-diligence assessment to support partner negotiations

Rapid multiple indication assessments

Rapid assessment of multiple ophthalmology orphan/non-orphan indications across the EU5 and the US

Rapid market opportunity assessment for an ATMP

Supporting a global pharmaceutical company with a market opportunity assessment to support commercial decision making

Asset/brand planning for a cell therapy

Supporting a global pharmaceutical company to plan for the launch of a new cell therapy